Artelo Biosciences Secures U.S. Patent Allowance for ART27.13 Commercial Formulation Through 2041

With two Phase 2 programs running concurrently, Artelo Biosciences has moved to lock down the intellectual property surrounding its intended commercial formulation of ART27.13, receiving a Notice of Allowance from the U.S. Patent and Trademark Office for claims covering compositions of the peripherally selective cannabinoid agonist dispersed in polyethylene glycol. The allowed claims are expected to extend patent protection through 2041, a timeline that directly shapes licensing conversations and manufacturing scale-up planning.

For development and regulatory teams tracking the program, the formulation specificity of the claims is the operative detail. Protection tied to the intended commercial formulation, rather than the molecule alone, reduces the risk of generic workarounds at the composition level and provides a defined IP perimeter for any future 21 CFR Part 211-compliant manufacturing transfer or partnership agreement. That distinction carries weight when CMO selection and tech-transfer timelines are being evaluated against Phase 2 readout schedules.

ART27.13 is currently being evaluated in the Phase 2 CAReS trial targeting cancer-related anorexia and the Phase 2 DREAM study in patients with glaucoma or ocular hypertension. Interim Phase 2 data from CAReS showed patients titrated to the highest dose of 1,300 µg achieved an average weight gain of approximately 6% over 12 weeks, while placebo patients lost an additional 5%. No FDA-approved treatment currently exists for cancer anorexia cachexia syndrome, which frames the regulatory pathway as an area of unmet need rather than a crowded indication.

The DREAM study, an investigator-led trial funded by Glaucoma UK and the HSC R&D Division, is evaluating a once-daily oral dose of 650 µg to reduce intraocular pressure, with initial results anticipated in Q4 2026. Two concurrent Phase 2 readouts within a compressed window will test the company's regulatory and CMC documentation infrastructure simultaneously.

ART27.13 was originally developed by AstraZeneca and has now been evaluated across seven clinical studies involving more than 280 participants, providing a clinical safety dataset that supports the formulation's development trajectory. The drug's peripheral selectivity for CB1 and CB2 receptors is designed to deliver systemic metabolic effects while limiting central nervous system exposure, a pharmacological profile that informs both the benefit-risk assessment and the labeling strategy.

The Q4 2026 DREAM readout will serve as the next measurable checkpoint for teams assessing whether the formulation's IP position translates into a viable commercial and partnership framework.

Source: Artelo Biosciences, Inc. via GlobeNewswire, August 17, 2026.